Home » About Microbicides » Testing & Trials » Current Trials
Current Trials
Multiple candidate microbicides with different target pathogens and mechanisms of action must be tested simultaneously. This increases the probability and speed of finding a successful microbicide, and with time will lead to a variety of products with different attributes for different users. The table below summarizes those products that are currently in clinical trials globally and beyond phase 1 in the trial process.
|
MICROBICIDE CANDIDATES IN ONGOING CLINICAL TRIALS Summary from July 2010
| ||||
|
Phase |
Candidate Name |
Sponsor* |
Sites by Country | |
|
IIB |
Tenofovir gel |
CAPRISA, USAID, LIFElab, African Dept of Science and Technology, Gilead, FHI, CONRAD |
South Africa | |
|
IIB |
Tenofovir gel |
CONRAD, DAIDS/NIAID, Gilead, MTN |
South Africa, Uganda, United States | |
|
I/II |
Dapivirine gel | IPM - safety and acceptability | Kenya, Malawi, Rwanda, South Africa, Tanzania | |
|
I/II |
Dapivirine gel | IPM - expanded safety study | United States | |
|
I/II |
Dapivirine vaginal ring | IPM - expanded safety study | South Africa | |
|
I/II |
VivaGel® (SPL7013 gel) |
Starpharma, NIAID, NIH |
Australia | |
Candidates Most Advanced in Clinical Trials
The following is a description of the candidate microbicide entering advanced trials. For more information on clinical trials of tenofovir, additional candidate microbicide products, and other HIV prevention products, please visit AVAC's Px Wire and Quarterly Update.
Tenofovir is a highly specific nucleotide reverse transcriptase inhibitor (NRTI). It is an antiretroviral drug. An oral formulation of tenofovir (trade name Viread) is actively marketed by Gilead Sciences for the treatment of HIV. For potential microbicide use, tenofovir has been formulated as a 1% gel. It is likely to be highly potent, so it only takes a small amount of the active ingredient to have an effect. It is non-contraceptive and HIV specific.